The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
Abstract
Purpose: ABI-007, the first biologically interactive albumin-bound paclitaxel in a nanameter particle, free of solvents, was compared with polyethylated castor oil–based standard paclitaxel in patients with metastatic breast cancer (MBC). This phase III study was performed to confirm preclinical studies demonstrating superior efficacy and reduced toxicity of ABI-007 compared with standard paclitaxel. Patients and Methods: Patients were randomly assigned to 3-week cycles of either ABI-007 260 mg/m 2 intravenously without premedication (n = 229) or standard paclitaxel 175 mg/m 2 intravenously with premedication (n = 225). Results: ABI-007 demonstrated significantly higher response rates compared with standard paclitaxel (33% v 19%, respectively; P = .001) and significantly longer time to tumor progression (23.0 v 16.9 weeks, respectively; hazard ratio = 0.75; P = .006). The incidence of grade 4 neutropenia was significantly lower for ABI-007 compared with standard paclitaxel (9% v 22%, respectively; P < .001) despite a 49% higher paclitaxel dose. Febrile neutropenia was uncommon (< 2%), and the incidence did not differ between the two study arms. Grade 3 sensory neuropathy was more common in the ABI-007 arm than in the standard paclitaxel arm (10% v 2%, respectively; P < .001) but was easily managed and improved rapidly (median, 22 days). No hypersensitivity reactions occurred with ABI-007 despite the absence of premedication and shorter administration time. Conclusion: ABI-007 demonstrated greater efficacy and a favorable safety profile compared with standard paclitaxel in this patient population. The improved therapeutic index and elimination of corticosteroid premedication required for solvent-based taxanes make the novel albumin-bound paclitaxel ABI-007 an important advance in the treatment of MBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Self-citationPharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Caveolae-deficient Endothelial Cells Show Defects in the Uptake and Transport of Albumin in Vivo
Schubert, W., Frank, P. G., Razani, B., Park, D. S., Chow, C.-W., & Lisanti, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100613200 · Cited by 337
(1999) · PubMed · Cited by 337
Role of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Postma, T. J., Vermorken, J. B., Liefting, A. J. M., Pinedo, H. M., & Heimans, J. J. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059220 · Cited by 271
Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270
Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer
John, T. A., Vogel, S. M., Tiruppathi, C., Malik, A. B., & Minshall, R. D. (2003) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00152.2002 · Cited by 269
Fang, J., Sawa, T., & Maeda, H. (2005) · Advances in Experimental Medicine and Biology · doi:10.1007/0-306-47932-x_2 · Cited by 221
Lorenz, W., Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., & Doenicke, A. (1977) · Agents and Actions · doi:10.1007/bf01964882 · Cited by 219
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
Tellingen, O. V., Huizing, M. T., Panday, V. R. N., Schellens, J. H. M., Nooijen, W. J., & Beijnen, J. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690696 · Cited by 211
Rowinsky, E. K., Chaudhry, V., Cornblath, D. R., & Donehower, R. C. (1993) · PubMed · Cited by 208
Transcytosis of plasma macromolecules in endothelial cells: A cell biological survey
Simionescu, M., Gafencu, A., & Antohe, F. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10086 · Cited by 207
Description of a short-term Taxol®-induced nociceptive neuropathy in rats
Authier, N., Gillet, J.-P., Fialip, J., Eschalier, A., & Coudore, F. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02910-3 · Cited by 171
Taxol Neuropathy: Electrodiagnostic and Sural Nerve Biopsy Findings
Sahenk, Z. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540190110024 · Cited by 163
Schiemann, B. J., Neil, J. R., & Schiemann, W. P. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-01-0001 · Cited by 159
Tabernero, J. M., Climent, M. A., Lluch, A. M., Albanell, J., Vermorken, J. B., Barnadas, A., Anton, A., Laurent, C., Mayordomo, J. I., Estaun, N., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh349 · Cited by 156
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein.
Kumar, G. N., Walle, U. K., Bhalla, K. N., & Walle, T. (1993) · PubMed · Cited by 98
Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.
Tahir, S. A., Ren, C., Timme, T. L., Gdor, Y., Hoogeveen, R. C., Morrisett, J. D., Frolov, A., Ayala, G., Wheeler, T. M., & Thompson, T. C. (2003) · PubMed · Cited by 86
Preclinical pharmacology of docetaxel
Bissery, M.-C. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00357-o · Cited by 83
Sparreboom, A., Verweij, J., van der Burg, M. E. L., Loos, W. J., Brouwer, E., Viganò, L., Locatelli, A., de Vos, A. I., Nooter, K., Stoter, G., et al. (1998) · PubMed · Cited by 82
Cited by
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationCancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
“In a Phase III study of 454 patients with metatastic breast cancer given Abraxane (260 mg per m 2 ) or Taxol (175 mg per m 2 ) intravenously every 3 weeks, response rates were significantly greater in patients treated with Abraxane than those receiving Taxo”
Method
Metadata
- Authors
- Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-11-01
- Volume
- 23
- Issue
- 31
- Pages
- 7794-7803
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153017356
- Cited by
- 2,153
- References
- 28
- FWCI
- 22.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.